See more : Leeku Industrial Co., Ltd. (025820.KS) Income Statement Analysis – Financial Results
Complete financial analysis of BioPorto A/S (THOXF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioPorto A/S, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Nan Ya Plastics Corporation (1303.TW) Income Statement Analysis – Financial Results
- Kingswood Holdings Limited (KWG.L) Income Statement Analysis – Financial Results
- China Electric Mfg. Corporation (1611.TW) Income Statement Analysis – Financial Results
- NAVER Corporation (035420.KS) Income Statement Analysis – Financial Results
- Southern BancShares (N.C.), Inc. PFD CV B (SBNCM) Income Statement Analysis – Financial Results
BioPorto A/S (THOXF)
About BioPorto A/S
BioPorto A/S, an in-vitro diagnostics company, provides diagnostic tests and antibodies to clinicians and researchers worldwide. The company offers the neutrophil gelatinase-associated lipocalin test, a particle-enhanced turbidimetric test that measures NGAL that is used to supplement clinical evaluation and standard tests; monoclonal antibodies for scientific, pharmaceutical, and clinical research use; enzyme-linked immunosorbent assay kits; IVD automated assays; and generic rapid assay device platform for the development of lateral flow assays. It sells its products through own sales team, distributors, and OEM partnerships. The company was founded in 2000 and is headquartered in Hellerup, Denmark.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 30.96M | 28.97M | 24.25M | 23.20M | 26.62M | 26.02M | 25.16M | 20.72M | 20.38M | 18.71M | 16.63M | 17.86M | 18.58M | 13.80M | 11.01M | 8.34M | 8.34M | 5.55M | 4.36M |
| Cost of Revenue | 10.78M | 9.93M | 9.21M | 9.87M | 9.29M | 8.18M | 6.91M | 5.03M | 4.90M | 5.51M | 7.58M | 6.80M | 8.06M | 5.34M | 4.75M | 4.62M | 4.62M | 2.42M | 4.49M |
| Gross Profit | 20.18M | 19.04M | 15.04M | 13.34M | 17.33M | 17.84M | 18.25M | 15.69M | 15.48M | 13.20M | 9.04M | 11.06M | 10.52M | 8.46M | 6.26M | 3.72M | 3.72M | 3.13M | -123.00K |
| Gross Profit Ratio | 65.19% | 65.73% | 62.01% | 57.49% | 65.09% | 68.55% | 72.54% | 75.74% | 75.95% | 70.55% | 54.39% | 61.91% | 56.61% | 61.28% | 56.85% | 44.58% | 44.58% | 56.43% | -2.82% |
| Research & Development | 25.45M | 34.94M | 30.26M | 28.13M | 24.56M | 18.68M | 21.93M | 9.67M | 9.94M | 8.62M | 10.21M | 9.91M | 8.13M | 8.90M | 8.64M | 6.38M | 6.38M | 7.64M | 6.68M |
| General & Administrative | 36.03M | 41.83M | 32.66M | 28.02M | 27.80M | 20.01M | 14.27M | 13.03M | 9.42M | 10.44M | 12.67M | 9.04M | 8.79M | 8.26M | 7.97M | 7.48M | 7.48M | 7.89M | 5.32M |
| Selling & Marketing | 18.87M | 21.22M | 17.38M | 20.79M | 39.27M | 20.94M | 18.55M | 18.04M | 8.88M | 9.40M | 5.97M | 5.97M | 6.46M | 4.71M | 5.67M | 3.90M | 3.90M | 2.26M | 2.23M |
| SG&A | 54.90M | 63.05M | 50.04M | 48.80M | 67.07M | 40.94M | 32.81M | 31.07M | 18.30M | 19.84M | 18.63M | 15.01M | 15.25M | 12.97M | 13.63M | 11.38M | 11.38M | 10.15M | 7.55M |
| Other Expenses | 1.01M | 274.00K | -548.00K | -474.00K | -591.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 81.35M | 97.99M | 80.30M | 76.93M | 91.63M | 59.62M | 54.74M | 40.74M | 28.24M | 28.45M | 28.85M | 24.92M | 23.38M | 21.87M | 22.28M | 17.76M | 16.78M | -11.53M | -14.48M |
| Cost & Expenses | 92.13M | 107.91M | 89.51M | 86.79M | 100.92M | 67.80M | 61.65M | 45.77M | 33.14M | 33.96M | 36.43M | 31.73M | 31.44M | 27.21M | 27.03M | 22.39M | 21.40M | -9.11M | -9.99M |
| Interest Income | 1.04M | 44.00K | 0.00 | 4.00K | 75.00K | 27.00K | 25.00K | 64.00K | 93.00K | 210.00K | 56.00K | -273.00K | 68.00K | 93.00K | 124.00K | 1.75M | 763.00K | 1.26M | 755.00K |
| Interest Expense | 571.00K | 1.09M | 912.00K | 780.00K | 326.00K | 38.00K | 31.00K | 29.00K | 279.00K | 15.00K | 1.68M | 1.82M | 2.05M | 889.00K | 61.00K | 125.00K | 982.00K | 190.00K | 153.00K |
| Depreciation & Amortization | 2.68M | 3.97M | 4.33M | 3.99M | 2.86M | 543.00K | 504.00K | 390.00K | 300.00K | 270.00K | 107.00K | 189.00K | 8.00K | 325.00K | 345.00K | 384.00K | 395.00K | 442.00K | 460.00K |
| EBITDA | -57.96M | -77.81M | -58.60M | -62.06M | -71.06M | -41.04M | -36.53M | -24.48M | -12.44M | -14.81M | -20.09M | -13.94M | -12.88M | -12.99M | -15.55M | -14.23M | -12.67M | -12.96M | 15.57M |
| EBITDA Ratio | -187.21% | -255.13% | -241.61% | -267.45% | -266.94% | -157.73% | -145.22% | -118.15% | -61.01% | -79.18% | -120.85% | -78.08% | -68.78% | -94.14% | -141.24% | -163.80% | -151.89% | 294.54% | 356.95% |
| Operating Income | -61.17M | -77.88M | -65.26M | -63.59M | -74.30M | -41.78M | -36.49M | -25.05M | -12.76M | -15.26M | -19.80M | -13.87M | -12.86M | -13.41M | -16.02M | -14.05M | -14.05M | 14.66M | 14.36M |
| Operating Income Ratio | -197.60% | -268.83% | -269.05% | -274.05% | -279.09% | -160.60% | -145.08% | -120.88% | -62.60% | -81.56% | -119.11% | -77.67% | -69.19% | -97.17% | -145.50% | -168.41% | -168.41% | 263.94% | 329.09% |
| Total Other Income/Expenses | -35.00K | -2.60M | 1.42M | -3.24M | 52.00K | 164.00K | -570.00K | 148.00K | -255.00K | 159.00K | -2.07M | -2.08M | -1.98M | -796.00K | 63.00K | -697.00K | -219.00K | 30.39M | 602.00K |
| Income Before Tax | -61.21M | -81.55M | -63.84M | -66.83M | -74.25M | -41.62M | -37.06M | -24.90M | -13.01M | -15.10M | -21.87M | -15.95M | -14.84M | -14.21M | -15.95M | -14.26M | -14.26M | 15.73M | 14.96M |
| Income Before Tax Ratio | -197.71% | -281.50% | -263.21% | -288.03% | -278.89% | -159.97% | -147.34% | -120.17% | -63.85% | -80.71% | -131.57% | -89.32% | -79.84% | -102.93% | -144.93% | -171.03% | -171.03% | 283.17% | 342.89% |
| Income Tax Expense | -4.88M | -5.62M | -6.73M | -5.27M | -4.61M | -3.57M | -4.82M | -2.10M | -2.28M | -2.17M | -1.25M | -1.25M | 68.00K | 93.00K | 124.00K | 0.00 | 982.00K | 32.71M | 30.67M |
| Net Income | -56.33M | -75.92M | -57.11M | -61.56M | -69.64M | -38.05M | -32.24M | -22.80M | -10.73M | -12.93M | -20.62M | -14.70M | -14.84M | -14.21M | -15.95M | -14.26M | -14.26M | -15.73M | -14.96M |
| Net Income Ratio | -181.95% | -262.08% | -235.48% | -265.31% | -261.60% | -146.25% | -128.18% | -110.04% | -52.65% | -69.10% | -124.05% | -82.32% | -79.84% | -102.93% | -144.93% | -171.03% | -171.03% | -283.17% | -342.89% |
| EPS | -0.16 | -0.23 | -0.21 | -0.29 | -0.27 | -0.19 | -0.18 | -0.14 | -0.07 | -0.09 | -0.21 | -0.19 | -0.21 | -0.20 | -0.24 | -0.22 | -0.27 | -0.39 | -0.39 |
| EPS Diluted | -0.16 | -0.23 | -0.21 | -0.29 | -0.27 | -0.19 | -0.18 | -0.14 | -0.07 | -0.09 | -0.21 | -0.19 | -0.21 | -0.20 | -0.24 | -0.22 | -0.27 | -0.39 | -0.39 |
| Weighted Avg Shares Out | 358.50M | 331.20M | 278.05M | 213.54M | 255.47M | 197.25M | 182.02M | 164.97M | 153.17M | 148.41M | 99.65M | 75.54M | 71.83M | 70.27M | 65.45M | 63.86M | 52.57M | 40.62M | 38.41M |
| Weighted Avg Shares Out (Dil) | 358.50M | 331.20M | 278.05M | 213.54M | 255.47M | 197.25M | 182.02M | 164.97M | 153.17M | 148.41M | 99.65M | 75.54M | 71.83M | 70.27M | 65.45M | 63.86M | 52.57M | 40.62M | 38.41M |
BioPorto modtager FDA godkendelse i USA vedrørende NGAL Test til identificering af risiko for akut nyresvigt hos børn i alderen 3 måneder til 21 år
8. december 2023 Pressemeddelelse BioPorto modtager FDA godkendelse i USA vedrørende NGAL Test til identificering af risiko for akut nyresvigt hos børn i alderen 3 måneder til 21 år BioPorto A/S har i går annonceret modtagelse af FDA-godkendelse (”510(k) clearance”) af...
BioPorto Receives FDA 510(k) Clearance for NGAL Test in the United States First Test to Aid in Assessing AKI Risk for Patients Aged 3 Months Through 21 Years
December 7, 2023 Announcement no. 20 BioPorto Receives FDA 510(k) Clearance for NGAL Test in the United States First Test to Aid in Assessing AKI Risk for Patients Aged 3 Months Through 21 Years COPENHAGEN, DENMARK and BOSTON, MA, December...
BioPorto Announces Two Poster Presentations at ASN Kidney Week 2023 Conference
November 1, 2023 News Release BioPorto Announces Two Poster Presentations at ASN Kidney Week 2023 Conference COPENHAGEN, Denmark and BOSTON, MA, USA, November 1, 2023, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused...
BioPorto Announces Interim Results and Business Update For the Third Quarter and Nine Months of Fiscal 2023
November 1, 2023 Announcement no. 18 BioPorto Announces Interim Results and Business Update For the Third Quarter and Nine Months of Fiscal 2023 COPENHAGEN, Denmark and BOSTON, MA, USA, November 1, 2023, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto) (CPH:BIOPOR) today...
BioPorto provides interim Q3 results and revised 2023 Financial Guidance.
October 31, 2023 Announcement no. 17 BioPorto provides interim Q3 results and revised 2023 Financial Guidance.
BioPorto A/S to Host Third Quarter 2023 Earnings Webcast and Analyst Call
October 20, 2023 News Release BioPorto A/S to Host Third Quarter 2023 Earnings Webcast and Analyst Call COPENHAGEN, Denmark and BOSTON, MA, USA, October 20, 2023, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company...
BioPorto A/S to Host Annual Earnings Webcast and Analyst Call
COPENHAGEN, DENMARK and BOSTON, MA, USA, March 23, 2023, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announced today that, in connection with...
BioPorto maintains guidance for 2022, posts US$2.9 million revenue for first nine months of year
BioPorto (NASDAQ COPENHAG:BIOPOR) has reported a 16% revenue increase in the first nine months of 2022 over the prior year, and maintained its revenue guidance of 24 to 27 million Danish kroner (DKr). For the nine months ended September 30, the Copenhagen...
BioPorto issues update on pipeline for its gRAD technology
BioPorto (NASDAQ COPENHAG:BIOPOR) A/S has said it is supporting Rigshospitalet (RH (NYSE:RH)), Copenhagen, with quantitative thrombomodulin tests based on its generic Rapid Assay Device (gRAD) technology. RH is investigating the potential for thrombomodulin blood levels to be used as a...
BioPorto A/S reports that its biomarker test was used in research study for seriously ill coronavirus patients
BioPorto (NASDAQ COPENHAG:BIOPOR) A/S, the diagnostics group, reported that one of its biomarker tests has been used in a research study on a potential treatment for seriously ill coronavirus (COVID-19) patients. Published research of the study carried out in Denmark...
Source: https://incomestatements.info
Category: Stock Reports